Zeki: /* =Dosages */

2024-12-01T08:28:57Z

=Dosages

← Older revision		Revision as of 04:28, 1 December 2024
Line 24:		Line 24:
	Oral		Oral

	==Dosages=		==Dosages==
	*Type 2 diabetes: Starting dose 5 mg once daily, can be increased to 10 mg once daily		*Type 2 diabetes: Starting dose 5 mg once daily, can be increased to 10 mg once daily
	*Heart failure: 10 mg once daily		*Heart failure: 10 mg once daily
Line 33:		Line 33:
	*eGFR <25 mL/min/1.73 mm<sup>2</sup>: Not recommended for initiation		*eGFR <25 mL/min/1.73 mm<sup>2</sup>: Not recommended for initiation

	7. Side Effects:		==Side Effects==
	{\| class="wikitable"		{\| class="wikitable"
	!style="text-align: left"\| Frequency		!style="text-align: left"\| Frequency

Zeki at 01:21, 8 July 2024

2024-07-08T01:21:44Z

← Older revision		Revision as of 21:21, 7 July 2024
Line 6:		Line 6:

	'''Dapagliflozin (FORXIGA)'''（中文：[[達格列淨]]）		'''Dapagliflozin (FORXIGA)'''（中文：[[達格列淨]]）
			==Common Strengths of Dapagliflozin Tablet==
			Dapagliflozin tablets are available in the following strengths:
			*5 mg and 10 mg tablets

			==Drug Trade Names of Metformin Tablet==
			Forxiga

			==Drug Usage==
			*Treatment of type 2 diabetes mellitus
			*Reducing the risk of major adverse cardiovascular events (including myocardial infarction, stroke or death) in adults with type 2 diabetes or who are at risk for cardiovascular disease.
			*Reduce the risk of hospitalization for heart failure in adults with type 2 diabetes and established cardiovascular disease

			==Mechanism of Action==
			Inhibits sodium-glucose co-transporter 2 (SGLT2) in the proximal renal tubules, reducing glucose reabsorption and increasing urinary glucose excretion.

			==Route of Administration==
			Oral

			==Dosages=
			*Type 2 diabetes: Starting dose 5 mg once daily, can be increased to 10 mg once daily
			*Heart failure: 10 mg once daily
			*Chronic kidney disease: 10 mg once daily
			Renal dose based on eGFR:
			*eGFR ≥45 mL/min/1.73 m<sup>2</sup>: No dose adjustment required
			*eGFR 25 to <45 mL/min/1.73 mm<sup>2</sup>: Not recommended for glycemic control, but may be continued for heart failure or CKD
			*eGFR <25 mL/min/1.73 mm<sup>2</sup>: Not recommended for initiation

			7. Side Effects:
			{\| class="wikitable"
			!style="text-align: left"\| Frequency
			!Adverse reactions
			\|-
			\| rowspan="3" \| '''Common
			\| Urinary tract infection
			\|-
			\| Genital infection
			\|-
			\| Increased urination
			\|-
			\| rowspan="3" \| '''Uncommon
			\| Diabetic ketoacidosis (DKA) - a condition where blood becomes too acidic
			\|-
			\| Hypoglycemia (low blood sugar), especially when combined with insulin or sulfonylureas
			\|-
			\| Hypotension
			\|}

			==Pharmacokinetics==
			*Absorption
			**Rapidly absorbed, peak plasma concentrations within 2 hours
			*Metabolism
			**Primarily through UGT1A9
			*Elimination:
			**Mean plasma terminal half-life approximately 12.9 hours
			*uration of action:
			**24 hours (allowing for once-daily dosing)

			==Drug Precautions==
			'''Pregnancy

			Not recommended

			'''Breastfeeding

			Not recommended

			'''Children and Elderly

			Not recommended for children under 10 years. No dose adjustment is required for elderly patients

			'''Renal Impairment

			Use with caution, dosage adjustments based on eGFR

			'''Monitoring Requirements

			Renal function, volume status, signs of ketoacidosis

			'''Drug Interaction

			May increase the risk of hypoglycemia when used with insulin or insulin secretagogues

			==FAQ==
			'''How Should I Take the Tablet?

			Take once daily in the morning, with or without food

			'''What Should I Avoid While Taking?

			Avoid excessive alcohol consumption and dehydration

			'''What Happens if I Miss a Dose?

			Take it as soon as you remember. If it is close to your next dose, skip the missed dose and continue with your regular schedule. Do not take a double dose.

Zeki: Created page with "Category: DrugsCategory: Sodium-glucose co-transporter 2 (SGLT2) inhibitor '''Antidiabetic Drug''' '''Drug class: :Category: Sod..."

2024-07-08T01:09:55Z

Created page with "Category: Drugs Category: Sodium-glucose co-transporter 2 (SGLT2) inhibitor '''Antidiabetic Drug''' '''Drug class: :Category: Sod..."

New page

[[Category: Drugs]][[Category: Sodium-glucose co-transporter 2 (SGLT2) inhibitor]]

[[:Category: Antidiabetic Drug | '''Antidiabetic Drug''']]

'''Drug class: [[:Category: Sodium-glucose co-transporter 2 (SGLT2) inhibitor | Sodium-glucose co-transporter 2 (SGLT2) inhibitor]]

'''Dapagliflozin (FORXIGA)'''（中文：[[達格列淨]]）

Dapagliflozin - Revision history

Zeki: /* =Dosages */

Zeki at 01:21, 8 July 2024

Zeki: Created page with "Category: DrugsCategory: Sodium-glucose co-transporter 2 (SGLT2) inhibitor '''Antidiabetic Drug''' '''Drug class: :Category: Sod..."